Actively Recruiting
Open-Label Phase 3 Study of Intravenous Neridronate for Complex Regional Pain Syndrome Type 1 Treatment
Led by Ambros Therapeutics, Inc. · Updated on 2026-10-16
135
Participants Needed
1
Research Sites
6 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating intravenous AMBTX-01 neridronate in an open-label Phase 3 extension study for adults with Complex Regional Pain Syndrome Type 1 CRPS-1. This study aims to assess the safety, tolerability, and effectiveness of neridronate in participants who previously completed a related randomized clinical trial. It focuses on managing persistent moderate-to-severe CRPS-1 symptoms, including pain and other signs, in a serious condition context. Participants will receive four 100 mg intravenous infusions of neridronate over two hours on Days 1, 4, 7, and 10. The study includes a screening period of up to 12 weeks, followed by the treatment infusions and a post-treatment follow-up lasting through Week 12. This open-label design allows all eligible participants to receive the active study medication. During the study, participants will be monitored through various assessments including safety evaluations for adverse events and laboratory tests. Researchers will measure changes in pain levels, CRPS severity scores, limb edema, temperature differences, and both patient and clinician impressions of health improvements at multiple time points up to 12 weeks. Total participation lasts approximately 24 weeks, including screening, treatment, and follow-up periods.
CONDITIONS
Brief Title
Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1
Research Team
M
Medical Affairs Ambros Therapeutics
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here